Becton Dickinson stock after-hours at EUR 160.65: plus 2.26 percent versus prior close
Becton Dickinson stock saw a 2.26 percent increase in after-hours trading, reaching EUR 160.65. This rise follows the company's strong fiscal third-quarter 2026 results, where it reported a 4.4 percent year-over-year revenue increase and a 4.9 percent rise in adjusted diluted earnings per share. Becton Dickinson also updated its fiscal 2026 outlook, anticipating revenue growth at the high end of its low-single-digit FX-neutral range and raising its adjusted diluted EPS guidance.
CPG Innovator: Supradeep Vankayala of Becton Dickinson
Supradeep Vankayala, Lead Design Engineer at Becton Dickinson, was recognized with a PMMI CPG NexGen award for developing a PFAS-free, recyclable, and sterilizable packaging solution. He discusses his career in packaging, the impact of AI on his work, and future trends in the pharma and medical device industry. Vankayala emphasizes patient safety, regulatory compliance, and sustainability as key drivers in packaging decisions.
RBC keeps Hold rating on Becton Dickinson stock
RBC Capital has reiterated its "Hold" rating on Becton Dickinson (BDX) stock, setting a price target of USD 190.00. The company reported strong third-quarter fiscal 2026 results, surpassing consensus estimates for both adjusted earnings per share and revenue. Becton Dickinson's stock is currently trading below its 52-week high, with the next earnings announcement scheduled for November 5, 2026.
Becton Dickinson stock pre-market at EUR 157.63: plus 0.34 percent
Becton Dickinson stock is trading pre-market at EUR 157.63, a 0.34 percent increase from its prior close. This comes amidst recent leadership changes, with Arthur Hu named executive vice president and chief information and digital officer, and the company celebrating 70 years of manufacturing at its Sandy, Utah facility.
BD marks 70 years in Utah; Becton Dickinson stock trades EUR 157.10 versus EUR 157.10 close
Becton Dickinson (BD) celebrated 70 years of manufacturing in Sandy, Utah, on September 29, 2026. The company's stock traded at EUR 157.10 in weekend trading, unchanged from its previous close. BD has invested over $100 million in the Sandy facility, which produces essential medical devices and employs more than 1,000 people.
Becton, Dickinson and Company (BDX) Stock forecasts
Argus has updated its outlook for Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. The report, authored by Senior Analyst David H. Toung, notes BD's operations across four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The current stock price for BDX is $176.80.
RBC Capital Remains a Hold on Becton Dickinson (BDX)
RBC Capital analyst Kendall Au maintained a Hold rating on Becton Dickinson (BDX) with a price target of $190.00. The company's recent earnings showed a quarterly revenue of $4.98 billion and a net profit of $377 million, down from the previous year. Corporate insider sentiment for BDX is negative, with an increase in insider selling over the past quarter.
Boston Scientific (BSX) Receives a Buy from RBC Capital
RBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. This aligns with a general "Strong Buy" consensus among analysts, predicting a 35.51% upside. The company recently reported strong quarterly revenues of $5.44 billion and a net profit of $907 million, alongside positive insider sentiment with increased insider stock purchases.
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Kendall Au reiterated a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $110.00. This affirmation follows the company's Q2 earnings report, which showed increased revenue and net profit compared to the previous year. Zimmer Biomet Holdings currently holds a Moderate Buy consensus among analysts, with an average price target of $106.07.
BD marks 70 years at Utah medtech manufacturing site
BD (Becton, Dickinson and Company) recently celebrated 70 years of manufacturing at its Sandy, Utah facility, a key site for producing peripheral intravenous (IV) catheters. The 650,000 sq ft facility, which employs over 1,000 people, is critical to the global supply of medical technologies. BD has invested more than $100 million in the site over the last five years, demonstrating its commitment to U.S. manufacturing and supporting healthcare systems worldwide.
Boston Scientific Corporation (BSX) Stock forecasts
This article provides an analyst report on Boston Scientific Corporation (BSX) by Morningstar. The report, dated October 2, 2026, highlights competitive pressures affecting key growth areas for the company, which specializes in less invasive medical devices. Debbie S. Wang, a Senior Equity Analyst, authored the report.
Argus Research Adjusts Becton, Dickinson and Company Price Target to $210 From $180, Maintains Buy Rating
Argus Research has increased its price target for Becton, Dickinson and Company (BDX) to $210 from $180, while reaffirming a Buy rating on the stock. The medical technology company also recently announced the appointment of Arthur Hu as its new Chief Information and Digital Officer, effective September 30, 2026. The article provides an overview of the company's business segments, geographic sales distribution, and other recent news and analyst actions.
STERIS (STE) Dividend Yield 2026, Date & History $STE
This article provides a detailed overview of STERIS (STE) dividend information for 2026, including its dividend yield, annual dividend, and payment history. STERIS pays quarterly dividends, has increased its dividend for 20 consecutive years, and maintains a healthy payout ratio. The report also compares STERIS's dividend performance against healthcare and NYSE averages and addresses frequently asked questions about its dividend.
Becton, Dickinson and Company (BDX) Stock Forecasts
Argus has updated its outlook on Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. Headquartered in Franklin Lakes, NJ, BD operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The report, dated October 1, 2026, was authored by David H. Toung, a Senior Analyst specializing in Medical Devices & Healthcare Services.
A 10% dividend increase is part of ResMed (RMD)'s FY2027 stockholder return plan.
ResMed (RMD) announced plans for over $1.85 billion in stockholder returns for fiscal year 2027, including approximately $1.5 billion in share repurchases and a 10% increase in the quarterly dividend to $0.66 per share. This strategy follows a strong fiscal year 2026 with 8% constant currency revenue growth and 17% non-GAAP diluted earnings per share growth. The company also detailed corporate governance changes, including the election of 10 directors and the ratification of PricewaterhouseCoopers LLP as its fiscal 2027 auditor.
Medtronic drug-coated balloon gets FDA breakthrough status
Medtronic has received FDA breakthrough device designation for its drug-coated balloon catheter designed to treat peripheral artery disease (PAD) below the knee. This is a significant development as current drug-coated balloons are not indicated for use in this area, which is historically difficult to treat and can lead to amputation. Medtronic plans a randomized pivotal trial with approximately 400 patients to study the effectiveness of its IN.PACT BTK paclitaxel-coated device.
Becton Dickinson stock last at EUR 20.72 at Lang & Schwarz on September 29, 2026
Becton Dickinson stock closed at EUR 20.72 at Lang & Schwarz on September 29, 2026. The company also announced the appointment of Arthur Hu as executive vice president and chief information and digital officer, effective September 30, 2026. Additionally, BD celebrated 70 years of manufacturing at its Sandy, Utah facility, where it has invested over $100 million in the past five years.
Becton Dickinson EVP Michael Feld sells $13,961 in BDX shares
Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (NYSE:BDX), sold 76 shares of the company's common stock for a total of $13,961 on September 28, 2026. This transaction was executed under a Rule 10b5-1 plan adopted in May 2026. Following the sale, Mr. Feld beneficially owns 19,644 shares.
Abbott launches SimpleScreen CRC, a blood-based colorectal cancer screening test for adults 45+, covered by Medicare.
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older. This test is covered by Medicare and aims to increase screening rates by offering a convenient alternative to traditional methods. Despite this new product, Abbott Laboratories (ABT) stock is trading near its 52-week low, with more selling pressure observed on the Pluang platform.
Evogene gets Nasdaq extension to regain $1 mini...
Evogene Ltd. has received an extension from Nasdaq until March 29, 2027, to regain compliance with the minimum $1 share price requirement to avoid delisting. The company must maintain a closing bid price of at least $1 for ten consecutive business days and is considering options like a reverse share split to meet this condition. This development provides market context, noting that the health sector saw mixed performance on September 30, 2026.
BDX.GE Bond Profile: Coupon and Redemption
This article provides a detailed profile of the BDX.GE bond issued by Becton, Dickinson and Company. It covers key information such as the issuer's profile, bond classification, credit risk assessment, interest payment details including a 6.70% semi-annual coupon, and a redemption schedule. The bond has a maturity date of August 1, 2028, and an outstanding amount of $85.05 million USD.
Form 4 Becton Dickinson and Co For: 29 September By Investing.com
This article reports on a Form 4 filing for Becton Dickinson and Co (BDX) on September 29, 2026. The Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. The article provides the title and date of the filing.
Becton Dickinson EVP Michael Feld sells $13,961 in BDX shares By Investing.com
Michael Feld, EVP and Chief Revenue Officer at Becton Dickinson & Co (NYSE:BDX), sold 76 shares of company stock for $13,961 on September 28, 2026, as part of a Rule 10b5-1 plan. Following the sale, Feld beneficially owns 19,644 shares. The transaction occurred while BDX trades at $181.97, with InvestingPro analysis suggesting the stock is undervalued.
An executive at Becton Dickinson (BDX) sells 76 shares at $183.70 each.
Michael Feld, EVP, Chief Revenue Officer at Becton Dickinson & Co. (BDX), sold 76 shares of common stock on September 28, 2026, at a price of $183.70 per share. This sale was executed under a Rule 10b5-1 plan adopted on May 27, 2026, and his holdings after the transaction totaled 19,644 shares.
Form 4 Becton Dickinson and Co For: 29 September By Investing.com
This article announces the filing of Form 4 for Becton Dickinson and Co, specifically for September 29th. It is a very brief financial news item from Investing.com, providing basic information about a regulatory filing. The content focuses on the mere announcement rather than details of the filing itself.
ETFs Investing in Becton, Dickinson and Company Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Becton, Dickinson and Company (BOX). It provides a detailed table of these funds, including their market value, weight of BOX stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify ETFs that include Becton, Dickinson and Company in their portfolios, offering diversification and accessibility.
3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth
This article highlights three medical device companies—Abbott Laboratories (ABT), Medtronic (MDT), and Becton Dickinson (BDX)—as stable dividend raisers offering solid yields for retirement portfolios. These companies benefit from consistent demand for their products, allowing them to increase dividends annually. The article details each company's dividend history, safety, and investment case, noting their strong free cash flow and modest forward earnings multiples.
BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
BD (Becton, Dickinson and Company) is celebrating 70 years of manufacturing in Sandy, Utah, highlighting its significant role in vascular access technology and its contribution to the global supply of essential medical devices. The Sandy facility, which employs over 1,000 people, produces hundreds of millions of IV catheters annually, reflecting BD's commitment to U.S. manufacturing and innovation. The company also announced a $10,000 grant to the Maliheh Free Clinic, reinforcing its dedication to community partnership and strengthening local organizations.
Intuitive Surgical price pierces price target - Forecast today - 29-09-2026
Intuitive Surgical (ISRG) has broken above its previous price target of $405.00, extending its gains. The stock's positive momentum is supported by an earlier breakout from a descending price channel and its position above the 50-day Simple Moving Average. Analysts maintain a bullish outlook, expecting the stock to target the $440.00 resistance level.
BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
BD (Becton, Dickinson and Company) is celebrating 70 years of manufacturing, innovation, and community partnership at its Sandy, Utah facility. The site, which employs over 1,000 people, produces critical medical devices like IV catheters and has seen over $100 million in investments for expansion and modernization. BD's commitment extends to community support, with a recent $10,000 grant to Maliheh Free Clinic and ongoing partnerships with local organizations and schools.
Beckton, Dickinson and Company price gains ground - Forecast today - 29-09-2026
Becton, Dickinson and Company (BDX) advanced in recent intraday trading, finding support at its 50-day Simple Moving Average and showing continued bullish signals. The stock's primary short-term uptrend remains in control, following an ascending trendline. The outlook remains bullish as long as support at $175.70 holds, with a target resistance level of $192.00.
Texas Instruments price reaches price target - Forecast today - 29-09-2026
Texas Instruments (TXN) stock has reached its previous price target of $280.00 and is showing bullish technical formations, supported by trading above its 50-day Simple Moving Average. Despite some bearish signals from overbought momentum indicators, the outlook remains bullish, with a potential target of $300.00 if it breaks above $280.00.
What Is Drawing Attention To Axogen (AXGN)?
Axogen (AXGN) has garnered attention due to recent share price movements, showing a decline over the past month and three months but significant gains over the last year. Despite the recent pullback, which has brought its price to approximately 11% below an estimated intrinsic value and 25% below the average analyst target, the company's valuation narrative suggests it is 19% undervalued at $53.22. However, the article also notes potential risks due to Axogen's reliance on its Avance Nerve Graft and a high P/S ratio compared to industry peers.
Becton, Dickinson stock gained 2.56 percent on September 25
Becton, Dickinson (BDX) stock increased by 2.56% on September 25, trading at USD 183.82, following its Q3 fiscal 2026 revenue of USD 4.98 billion and adjusted EPS of USD 3.23, both exceeding analyst expectations. Despite the gain, the stock remains 4.79% below its 52-week high, with an average 12-month price target of USD 187.67. The company's next earnings report is scheduled for November 5, 2026.
West Pharmaceutical Services, Inc. (WST) Latest Stock News & Headlines - Yahoo Finance
This article provides a compilation of recent news headlines and performance data for West Pharmaceutical Services, Inc. (WST) from Yahoo Finance. It highlights various analyst recommendations and updates from different financial news sources regarding WST and related healthcare companies. The article also includes stock performance metrics for WST compared to the S&P 500.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
Becton, Dickinson and Company (BDX) is positioned for growth due to its strategic transformation into a pure-play MedTech company, emphasizing innovation, and strategic partnerships. Despite strong fiscal results and a positive outlook, the company faces challenges from macroeconomic headwinds, reimbursement uncertainties, and intense competition. Investors are advised to retain the stock, with a Zacks Rank #3 (Hold), as it focuses on sustainable growth and margin expansion.
US75887CS6 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Becton, Dickinson and Company 5.11% 08-FEB-2034 bond (US75887CS6). It covers key facts about the issuer, bond classification, credit risk assessment, interest payment details including a semi-annual fixed rate coupon, and bond redemption information. The bond has an issue date of February 8, 2024, a maturity date of February 8, 2034, and a face value of $1,000.00 USD.
Becton Dickinson stock heads into the open after closing at USD 166.35
Becton Dickinson (NYSE: BDX) closed at USD 166.35 on September 24, 2026, down 0.6 percent, while the S&P 500 fell 0.02 percent. The article notes the stock's performance relative to the index and mentions the estimated next earnings date of November 5, 2026, and the ex-dividend date of September 9, 2026, as US exchanges prepare to open for September 25.
Becton Dickinson stock falls 1.28 percent on September 24, 2026
Becton Dickinson's stock fell by 1.28% to USD 180.19 on September 24, 2026, trading below its 52-week high despite reporting a 4.4% year-over-year revenue increase to USD 5.0 billion in fiscal Q3 2026. The company's adjusted EPS reached USD 3.23, and fiscal 2026 guidance was raised to USD 12.62 to USD 12.72, though profitability was impacted by a 130-basis-point decline in adjusted operating margin. The article highlights that while Becton Dickinson is growing, factors like tariffs and portfolio effects are limiting operating profit, making execution and cost control crucial for future performance.
Becton Dickinson stock falls 1.26 percent as AI chief joins
Becton, Dickinson and Company's stock (BDX) fell 1.26% on September 24, 2026, as the company announced Arthur Hu would join as Chief Information and Digital Officer. This leadership change coincides with strong Q3 FY26 earnings, where revenue reached $5.0 billion and adjusted EPS beat consensus. Despite the positive earnings and digital transformation focus, the stock traded below its yearly high.
BD hires Arthur Hu as chief information and digital officer
Becton Dickinson (BD) has appointed Arthur Hu, formerly of Lenovo, as its new chief information and digital officer, effective September 30. BD CEO Tom Polen highlighted Hu's extensive technology experience as crucial for the company's focus on digital transformation and embedding artificial intelligence into its operations to drive innovation and business outcomes. Hu will succeed Denise Russell Fleming, who is retiring at the end of the year.
Biodesix Announces Progress on Tumor-Informed and Tumor-Naïve MRD Programs with Bio-Rad and Thermo Fisher
Biodesix, Inc. has announced significant progress in its collaborative programs with Bio-Rad Laboratories and Thermo Fisher Scientific to develop both tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions. These solutions aim to improve cancer monitoring by detecting circulating tumor DNA (ctDNA) post-treatment, offering highly sensitive tracking of tumor characteristics and broader access for patients without sufficient tissue samples. The company plans to present additional data at upcoming conferences, highlighting its expansion beyond lung diagnostics into precision oncology.
Intuitive Surgical, Inc. (ISRG) Options Chain - Yahoo Finance
This article provides the options chain for Intuitive Surgical, Inc. (ISRG) on Yahoo Finance. It indicates that there are currently no calls or puts available, with options data delayed by 15 minutes. The page also displays current stock information for ISRG, showing a price of 396.65 with a -1.35% change as of 1:49:36 p.m. EDT.
Parsippany Engineer Dr. Trivikrama Reddy Recognized with Inaugural BD Community Excellence Award for Global Community Impact
Dr. Trivikrama Reddy, a Parsippany resident and engineer at BD, has received the inaugural BD Community Excellence Award for his over fifteen years of volunteer service. He was recognized for significant contributions including bringing safe drinking water to an Indian tribal village and promoting STEM education. The award includes a $10,000 charitable grant to a non-profit of his choice.
Becton Dickinson stock holds at USD 180.70 as earnings near
Becton Dickinson's stock closed at USD 180.70, 6.4% below its 52-week high, as the company approaches its next earnings report on November 5, 2026. For Q3 fiscal 2026, BD reported revenues of USD 4.98 billion and adjusted earnings per share of USD 3.23, beating estimates by USD 0.09. Bank of America Securities raised its price target for Becton Dickinson to USD 200, maintaining a Neutral rating.
Becton, Dickinson and Company (BDX) Appoints Arthur Hu as Chief Information and Digital Officer
Becton, Dickinson and Company (BDX) has appointed Arthur Hu as Executive Vice President and Chief Information and Digital Officer, effective September 30, 2026. He will succeed Denise Russell Fleming, who is set to retire at the end of 2026. This move is seen as an early step in BD's digital and AI enablement strategy, with potential impacts on cost savings, productivity, and revenue growth.
Arthur Hu to Join BD as Chief Information and Digital Officer
BD (Becton, Dickinson and Company) announced that Arthur (Art) Hu will join the company as executive vice president and chief information and digital officer, effective September 30. Hu brings extensive experience in leading global technology and digital transformation initiatives, having previously served as senior vice president, global chief information officer, and chief technology and delivery officer at Lenovo Group. His appointment is expected to significantly strengthen BD's leadership in integrating digital capabilities, AI, and automation to drive innovation and operational excellence in the MedTech sector.
Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer
Becton, Dickinson and Company has appointed Arthur Hu as its new Chief Information and Digital Officer. The announcement was made on September 21, 2026. This leadership change is part of broader management adjustments at the company, which has seen other recent appointments and a retirement.
Two global health firms plan layoffs in metro Phoenix
Two global health firms, West Pharmaceutical Services Inc. and Becton, Dickinson and Co., are planning layoffs in the Phoenix metropolitan area. West Pharmaceutical Services will lay off 98 employees in Scottsdale due to ceasing operations on a product line, while Becton, Dickinson and Co. is moving its manufacturing operations to other facilities.
CDC Highlights Significant Increase in U.S. Rabies
Kamada Ltd. confirmed it has sufficient KedRAB® supply to meet increased U.S. demand following a CDC Health Advisory reporting a significant year-over-year increase in human rabies exposures and immunoglobulin utilization. KedRAB is one of only two FDA-approved anti-rabies immunoglobulin products, and Kamada is prepared to address the heightened need for this life-saving treatment. The CDC estimates approximately 1.4 million people in the U.S. seek medical care for possible rabies exposure annually.
